Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

Lilly said the plant will strengthen its global supply chain and expand the capacity for its growing portfolio of oral ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Eli Lilly plans to build a $3 billion manufacturing facility in the Netherlands to expand its capacity to produce oral medicines. The pharmaceutical company said Monday that the new facility will be ...

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the ...

The facility is expected to produce oral medications, including Lilly's highly anticipated GLP-1 pill for weight loss, orforglipron.

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

The Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and ...

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...